Jonathan M Raviotta1, Kenneth J Smith2, Jay DePasse3, Shawn T Brown3, Eunha Shim4, Mary Patricia Nowalk5, Angela Wateska2, Glenson S France6, Richard K Zimmerman5. 1. Department of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: raviottaj@upmc.edu. 2. Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 3. Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, United States. 4. Department of Mathematics, Soongsil University, Seoul, South Korea. 5. Department of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 6. Department of Economics, University of Pittsburgh, Greensburg, PA, United States.
Abstract
PURPOSE: High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This analysis models the public health impact and cost-effectiveness (CE) of these vaccines for 50-64year-olds. METHODS: Markov model CE analysis compared 5 strategies in 50-64year-olds: no vaccination; only standard-dose IIV3 offered (SD-IIV3 only), only quadrivalent influenza vaccine offered (SD-IIV4 only); high-risk patients receiving HD-IIV3, others receiving SD-IIV3 (HD-IIV3 & SD-IIV3); and high-risk patients receiving HD-IIV3, others receiving SD-IIV4 (HD-IIV3 & SD-IIV4). In a secondary analysis, RIV replaced HD-IIV3. Parameters were obtained from U.S. databases, the medical literature and extrapolations from VE estimates. Effectiveness was measured as 3%/year discounted quality adjusted life year (QALY) losses avoided. RESULTS: The least expensive strategy was SD-IIV3 only, with total costs of $99.84/person. The SD-IIV4 only strategy cost an additional $0.91/person, or $37,700/QALY gained. The HD-IIV3 & SD-IIV4 strategy cost $1.06 more than SD-IIV4 only, or $71,500/QALY gained. No vaccination and HD-IIV3 & SD-IIV3 strategies were dominated. Results were sensitive to influenza incidence, vaccine cost, standard-dose VE in the entire population and high-dose VE in high-risk patients. The CE of RIV for high-risk patients was dependent on as yet unknown parameter values. CONCLUSIONS: Based on available data, using high-dose influenza vaccine or RIV in middle-aged, high-risk patients may be an economically favorable vaccination strategy with public health benefits. Clinical trials of these vaccines in this population may be warranted.
PURPOSE: High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This analysis models the public health impact and cost-effectiveness (CE) of these vaccines for 50-64year-olds. METHODS: Markov model CE analysis compared 5 strategies in 50-64year-olds: no vaccination; only standard-dose IIV3 offered (SD-IIV3 only), only quadrivalent influenza vaccine offered (SD-IIV4 only); high-risk patients receiving HD-IIV3, others receiving SD-IIV3 (HD-IIV3 & SD-IIV3); and high-risk patients receiving HD-IIV3, others receiving SD-IIV4 (HD-IIV3 & SD-IIV4). In a secondary analysis, RIV replaced HD-IIV3. Parameters were obtained from U.S. databases, the medical literature and extrapolations from VE estimates. Effectiveness was measured as 3%/year discounted quality adjusted life year (QALY) losses avoided. RESULTS: The least expensive strategy was SD-IIV3 only, with total costs of $99.84/person. The SD-IIV4 only strategy cost an additional $0.91/person, or $37,700/QALY gained. The HD-IIV3 & SD-IIV4 strategy cost $1.06 more than SD-IIV4 only, or $71,500/QALY gained. No vaccination and HD-IIV3 & SD-IIV3 strategies were dominated. Results were sensitive to influenza incidence, vaccine cost, standard-dose VE in the entire population and high-dose VE in high-risk patients. The CE of RIV for high-risk patients was dependent on as yet unknown parameter values. CONCLUSIONS: Based on available data, using high-dose influenza vaccine or RIV in middle-aged, high-risk patients may be an economically favorable vaccination strategy with public health benefits. Clinical trials of these vaccines in this population may be warranted.
Authors: Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges Journal: Vaccine Date: 2007-04-20 Impact factor: 3.641
Authors: Jonathan M Raviotta; Kenneth J Smith; Jay DePasse; Shawn T Brown; Eunha Shim; Mary Patricia Nowalk; Richard K Zimmerman Journal: J Am Geriatr Soc Date: 2016-10-06 Impact factor: 5.562
Authors: Bruce Y Lee; Sarah M Bartsch; Shawn T Brown; Philip Cooley; William D Wheaton; Richard K Zimmerman Journal: Med Care Date: 2015-03 Impact factor: 2.983
Authors: Bryan R Luce; Kristin L Nichol; Robert B Belshe; Kevin D Frick; Su Xia Li; Audra Boscoe; Matthew D Rousculp; Parthiv J Mahadevia Journal: Vaccine Date: 2008-05-06 Impact factor: 3.641
Authors: Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery Journal: Clin Infect Dis Date: 2016-10-04 Impact factor: 20.999
Authors: Andrea C Tricco; Ayman Chit; Charlene Soobiah; David Hallett; Genevieve Meier; Maggie H Chen; Mariam Tashkandi; Chris T Bauch; Mark Loeb Journal: BMC Med Date: 2013-06-25 Impact factor: 8.775
Authors: Aitor Nogales; Gines Ávila-Pérez; Javier Rangel-Moreno; Kevin Chiem; Marta L DeDiego; Luis Martínez-Sobrido Journal: J Virol Date: 2019-05-01 Impact factor: 5.103
Authors: Samantha M Harrison; Melissa Y Wei; Lois E Lamerato; Joshua G Petrie; Emily Toth Martin Journal: Vaccine Date: 2018-05-07 Impact factor: 3.641
Authors: Aitor Nogales; Teresa Aydillo; Gines Ávila-Pérez; Alba Escalera; Kevin Chiem; Richard Cadagan; Marta L DeDiego; Feng Li; Adolfo García-Sastre; Luis Martínez-Sobrido Journal: Front Microbiol Date: 2019-12-17 Impact factor: 5.640